Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

• Status: Recruiting
• Trial end date: 2023-03-01

Summary

BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) and clofazimine (CFZ) compared to the current South African Standard of Care (Control Strategy) for 9 months for the treatment of rifampicin resistant (RR-TB) Tuberculosis.

• Phase: Phase 3

Details

• Lead Sponsor: Wits Health Consortium (Pty) Ltd
• Collaborators: Perinatal HIV Research Unit of the University of the Witswatersrand; Regents of the University of California; University of Cape Town
• Treatments: Bedaquiline; Clofazimine; Diarylquinolines; Ethambutol; Fluoroquinolones; Isoniazid; Levofloxacin; Linezolid; Ofloxacin; Pyrazinamide; Rifampin